Business Wire

Scientist.com Expands Award-Winning COMPLi ® Platform to include VERIF.i ® , a Supplier Pre-assessment Program

Share

Scientist.com, the healthcare industry’s leading marketplace for life science research, announced today the launch of VERIF.i®, a standardized supplier pre-assessment program. Research organizations use VERIF.i to evaluate the facilities, personnel and processes supporting the sourcing of human biological samples and research services involving animals. Supplier pre-assessments improve quality management, reduce costs and reduce risk.

“VERIF.i enables suppliers to differentiate themselves from their peers while also enabling customers to gain valuable, unbiased insight into their procedures and expertise,” stated Matt McLoughlin, Scientist.com's VP of Compliance & Categories. “The program streamlines the proactive assessment of suppliers, reducing costs and saving time.”

On-site assessments are expensive, resource intensive and time consuming for customers and suppliers. Scientist.com developed VERIF.i to provide a new approach to supplier pre-assessments that helps both sides of the market. Independent 3rd party auditors use a customized, industry developed checklist to confirm that a supplier’s facilities, processes and systems meet a customer’s research and regulatory requirements. The pre-assessments help customers select suppliers in an accelerated manner with more confidence and less risk.

“For all projects, our international team of auditors employs quality control measures and follows appropriate SOPs to ensure that our work meets each client’s high standards,” stated Cheri A. Wilczek, President and Founder of ClinAudits. “As an independent, 3rd party auditing and consulting organization, we provide Scientist.com’s client base with an additional layer of due diligence when using VERIF.i pre-assessments to decide which suppliers to work with for their individual organization.”

To learn more about VERIF.i, including how to sign up, visit scientist.com/verifi

About Scientist.com

Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saving time and money, reducing risk and providing access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, the Biotechnology Innovation Organization (BIO) and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised $39 million from 5AM Ventures, Leerink Transformation Partners and Heritage Provider Network among others.

Visit scientist.com to learn more.

Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram

Contact information

Sean Preci
Director of Communications
+1 858 455-1300 ext. 401
marketing@scientist.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome2.7.2020 10:00:00 CESTPress release

EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling. Lee Morley, Chief Executive Officer, EUSA Pharma, said:“Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production – the so-called ‘cytokine storm’ – wi

Deenova Multiplies its Pharmacy Automation Market Presence into 7 European Countries2.7.2020 09:34:00 CESTPress release

Deenova reported today its 2020 step-by-step but relentless continued geographic expansion into Austria, Belgium, France, Germany, Portugal, Spain, and Switzerland, with three new and seasoned business development staff totaling 66 years of healthcare industry experience. Christophe Jaffuel, Deenova’s International Business Development Director, stated: “I am extremely pleased to add Carlos Duran (formerly from Becton Dickinson-Carefusion-Rowa), Thierry Geraud (previously from Becton Dickinson-Carefusion-Pyxis) and Hilmi Sunay (recently from Omnicell-Health Robotics and Arxium-IHS Riva) to an already strong Deenova sales team. These 3 extremely talented and experienced individuals joined Deenova because of its unique technology and business approach to R.O.I., and total service solutions proven in the health care industry. I was equally impressed with Deenova’s demonstrated results when I joined the company 6 months ago, witnessing first-hand how Deenova simultaneously improves patient

Telstra Wholesale deploys ADVA technology in Australian-first Ethernet service2.7.2020 09:00:00 CESTPress release

ADVA (FSE: ADV) today announced that Telstra Wholesale has deployed its FSP 150 packet edge device with LTE backup to deliver the new Ethernet Access – Mobile Backup service. Unique to the Australian market, the offering improves service availability and strengthens business continuity. With Layer 2 mobile backup capabilities, ADVA’s technology automatically switches traffic to Telstra Wholesale’s 4G mobile network if fiber connectivity fails. This helps to provide peace of mind for enterprise customers that no longer have the burden of configuring costly mobile backup and recovery systems. The new service is the latest stage in a long-standing partnership between ADVA and Telstra Wholesale, which has been key to advancing the reliability and resiliency of Ethernet services for Telstra Wholesale customers throughout Australia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200702005024/en/ ADVA’s packet edge technology is he

Urethral Stricture Treatment by Hybrid Cell Therapy, Granted Japanese Patent2.7.2020 08:00:00 CESTPress release

Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer duration of relief to patients who had recurrence of the disease after earlier conventional treatments, has been reported by this method called “Bees-Haus” (Buccal epithelium Expanded and Encapsulated in Scaffold‐Hybrid Approach to Urethral Stricture; https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701006026/en/ Biomaterial research facility of JBM in Tokyo, where improvised scaffolds for regenerative medicine applications like Bees-haus, implants and medical devices are developed. (Photo: Business Wire) Male urethra, a tubular passage to let the urine out from urinary bladder, when affected with narrowing or stricture of the lumen, causes difficulty in voiding urine, urinary retention, and pain

Two in Five Fortune 500 Companies Choose Alibaba Cloud2.7.2020 08:00:00 CESTPress release

Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, said today it has supported 38 percent of the Fortune 500 companies over the past fiscal year. With this milestone, the cloud service provider plans to accelerate its globalization strategy, aiming to become the world’s leading digital intelligence backbone in three years. “We are extremely confident in the future of the global digital economy, especially with the digitalization of healthcare, business, education, leisure and other parts of our lives during the pandemic. As the largest cloud service provider in the Asia Pacific region, we will continue increasing investments in the next three years to strengthen our infrastructure, our solutions and our role in the wider technology ecosystem towards being the trusted partner of choice not just in Asia Pacific, but for the global digital economy by 2023,” said Jeff Zhang, president of Alibaba Cloud Intelligence, at the Alibaba Cloud Summit 2020 event. Cons

Alibaba Cloud and Unilever to Usher in Next-Generation Digital Marketing Initiatives2.7.2020 08:00:00 CESTPress release

Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, is partnering with Unilever, one of the biggest multinational consumer goods companies, in a pioneering strategic initiative that will enable Unilever to action on next-generation digital marketing campaigns. In the partnership, Unilever will be able to utilize Alibaba Cloud’s trusted artificial intelligence (AI) and cloud-based technologies to optimize its omni-channel, online and offline demand generation activities. With intelligent analysis, Alibaba Cloud’s solutions can help to unlock detailed insights into Unilever’s customers buying patterns and behavior. The data-driven business intelligence could help Unilever accelerate the creation of new and precisely targeted digital marketing campaigns. It could also enable Unilever to predict more precisely and quickly respond to changing customer buying habits across multiple platforms. Taking Unilever’s digital marketing to the next level, Alibaba Cloud’s